Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong appetite for its widely popular weight-loss ...

Eli Lilly said on Wednesday it will invest more than $1.2 billion to expand its manufacturing site in Puerto Rico, as the ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

Eli Lilly said its investigational oral GLP-1 weight-loss drug, orforglipron, met its primary endpoints in two recent phase 3 trials. The medicine company said Wednesday the drug met the primary and ...

(Reuters) -Telehealth company HealthTap said on Wednesday it is joining Eli Lilly's digital healthcare platform, LillyDirect, to offer virtual diabetes management services. Diabetic patients across ...

Mounjaro and Zepbound have helped boost the company's market cap. New data indicate these drugs do more than just help patients lose weight, contributing to potentially lowering risks to hearts and ...

Eli Lilly's stock price has been rangebound for most of the past two years. Sales of existing and upcoming diabetes and obesity treatments are likely to continue growing at a rapid clip. While Lilly's ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer put under the microscope. Cramer highlighted the importance of the company’s GLP-1 drug, as he stated: “I suggest, for example, that ...